SCHEMBL25870821

SCHEMBL25870821

CC(C)c1ccc([N+](=O)[O-])c(N2CCCC2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.63
▸ ALDH1A1 P00352 9/20 0.63
▸ CYP1A2 P05177 3/20 0.63
▸ CYP2C19 P33261 3/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ POLB P06746 2/20 0.61
▸ LMNA P02545 1/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ MAPK1 P28482 4/20 0.52
▸ ALDH1A3 P47895 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ APP P05067 1/20 0.50
▸ CTSB P07858 1/20 0.50
▸ AR P10275 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ KMT2A Q03164 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22455919 0.87 MAPT (0.60) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL10153002 0.87 GAA (0.64) MAPTALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL25442201 0.85 MAPT (0.52) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL22455933 0.85 ALDH1A1 (0.55) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL25442202 0.84 MAPT (0.56) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL25442200 0.81 MAPT (0.43) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL20279143 0.80 ALDH1A1 (0.50) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL8794400 0.80 ALDH1A1 (0.69) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL20279747 0.79 ALDH1A1 (0.50) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL15071215 0.79 MAPT (0.56) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF MAPT 235/4885ALDH1A1 2317/4885CYP1A2 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback